Cell-mediated immunologic mechanism and severity of TEN

Archives of Dermatology

Volumn 141, Issue 6, 2005, Pages 775-776

  Faye, Ousmane ^b   Wechsler, Janine ^b   Roujeau, Jean Claude ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; GLUCOSE;

BICARBONATE BLOOD LEVEL; BODY SURFACE; BURN; CELLULAR IMMUNITY; DISEASE SEVERITY; EDITORIAL; EPIDERMOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; MORTALITY; PATHOLOGY; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; COMPARATIVE STUDY; FEMALE; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; NEEDLE BIOPSY; NOTE; PHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL;

BIOPSY, NEEDLE; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 21844434217     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.6.775     Document Type: Editorial

References (17)

1. Shöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127:839-842.
2. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141:683-687.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.
4. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.
5. Monafo WW. Current concepts: initial management of burns. N Engl J Med. 1996;335:1581-1586.
6. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153.
7. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol. 2004;140:890-892.
8. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81-88.
9. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Piérard GE. Macrophage and tumor necrosis factor Α in toxic epidermal necrolysis. Arch Dermatol. 1994;130:605-608.
10. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
11. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous Immunoglobulins. Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26-32.
12. Bachot N, Revuz J, Roujeau JC. Intravenous Immunoglobulin treatment for Stevens-Johson Syndrome and toxic epidermal necrolysis. Arch Dermatol. 2003;139:33-36.
13. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246-255.
14. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355-361.
15. Miyauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y. T-cell subsets in druginduced toxic epidermal necrolysis: possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol. 1991;127:851-855.
16. Correia O, Delgado L, Ramos JP, Resende C, Fleming-Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129:466-468.
17. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114:1209-1215.